Payment overview · 2025
General Payments
$190.26
9 reported records · 4 companies
Healthcare provider profile · identity verified
Michael S Barris, MD
Allopathic & Osteopathic Physicians|Family Medicine · ABILENE, TX · NPI 1386671204
Verified facts
What the public records show
CMS Open Payments records show Michael S Barris, MD received $190.26 in general payments during 2025 across 9 reported records.
PFIZER INC. accounted for 58.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto, Jardiance.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $111.65 | 58.7% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $44.60 | 23.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.61 | 9.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.40 | 8.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $190.26 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $111.65 | 5 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $91.50 | 4 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $22.72 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $21.88 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $20.15 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $18.61 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.40 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 136 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 129 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
129 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
99 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
72 | 14 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
136 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 731 | 113 |
| Atorvastatin Calcium | Atorvastatin Calcium | 478 | 86 |
| Amlodipine Besylate | Amlodipine Besylate | 476 | 89 |
| Fluticasone Propionate | Fluticasone Propionate | 391 | 70 |
| Lisinopril | Lisinopril | 388 | 71 |
| Pantoprazole Sodium | Pantoprazole Sodium | 353 | 77 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 309 | 66 |
| Montelukast Sodium | Montelukast Sodium | 270 | 37 |
| Losartan Potassium | Losartan Potassium | 267 | 58 |
| Gabapentin | Gabapentin | 251 | 50 |
| Furosemide | Furosemide | 250 | 54 |
| Escitalopram Oxalate | Escitalopram Oxalate | 238 | 46 |
| Potassium Chloride | Potassium Chloride | 232 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 231 | 53 |
| Metformin Hcl | Metformin Hcl | 217 | 41 |
| Omeprazole | Omeprazole | 208 | 30 |
| Famotidine | Famotidine | 177 | 22 |
| Trazodone Hcl | Trazodone Hcl | 173 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 172 | 45 |
| Pregabalin | Pregabalin | 150 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 141 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 141 | 30 |
| Eliquis | Apixaban | 136 | 19 |
| Bupropion Xl | Bupropion Hcl | 133 | 25 |
| Buspirone Hcl | Buspirone Hcl | 133 | 20 |
| Jardiance | Empagliflozin | 129 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 123 | 29 |
| Sertraline Hcl | Sertraline Hcl | 120 | 17 |
| Meloxicam | Meloxicam | 113 | 22 |
| Mirtazapine | Mirtazapine | 112 | 20 |
| Tramadol Hcl | Tramadol Hcl | 106 | 23 |
| Prednisone | Prednisone | 104 | 62 |
| Nystatin | Nystatin | 100 | 26 |
| Mounjaro | Tirzepatide | 99 | 14 |
| Topiramate | Topiramate | 95 | 13 |
| Carvedilol | Carvedilol | 91 | 15 |
| Clonidine Hcl | Clonidine Hcl | 91 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 90 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 88 | 18 |
| Simvastatin | Simvastatin | 88 | 16 |
| Farxiga | Dapagliflozin Propanediol | 86 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 86 | 16 |
| Ozempic | Semaglutide | 86 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 83 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 81 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 74 | suppressed |
| Trulicity | Dulaglutide | 72 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 71 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 70 | 13 |
| Aripiprazole | Aripiprazole | 67 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 66 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 66 | 24 |
| Xarelto | Rivaroxaban | 65 | suppressed |
| Spironolactone | Spironolactone | 63 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 62 | 51 |
| Doxycycline Hyclate | Doxycycline Hyclate | 61 | 42 |
| Ezetimibe | Ezetimibe | 60 | 11 |
| Divalproex Sodium | Divalproex Sodium | 59 | suppressed |
| Alprazolam | Alprazolam | 58 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 58 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 56 | 12 |
| Fluconazole | Fluconazole | 54 | 32 |
| Donepezil Hcl | Donepezil Hcl | 53 | 11 |
| Allopurinol | Allopurinol | 51 | suppressed |
| Levetiracetam | Levetiracetam | 51 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 50 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 50 | 14 |
| Clonazepam | Clonazepam | 46 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 46 | 11 |
| Alendronate Sodium | Alendronate Sodium | 45 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Azithromycin | Azithromycin | 43 | 23 |
| Mupirocin | Mupirocin | 43 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 42 | suppressed |
| Baclofen | Baclofen | 41 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 41 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 39 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Carbamazepine | Carbamazepine | 36 | suppressed |
| Entresto | Sacubitril/Valsartan | 36 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 36 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | suppressed |
| Lamotrigine | Lamotrigine | 35 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 34 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 34 | 22 |
| Glipizide | Glipizide | 33 | suppressed |
| Lorazepam | Lorazepam | 33 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 33 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 32 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Finasteride | Finasteride | 31 | suppressed |
| Glipizide Er | Glipizide | 31 | suppressed |
| Methocarbamol | Methocarbamol | 31 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 31 | suppressed |
| Erythromycin | Erythromycin Base | 29 | suppressed |
| Latanoprost | Latanoprost | 29 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 29 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Lactulose | Lactulose | 27 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 27 | 11 |
| Azelastine Hcl | Azelastine Hcl | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | suppressed |
| Naproxen | Naproxen | 26 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 25 | suppressed |
| Hydrocortisone | Hydrocortisone | 25 | suppressed |
| Risperidone | Risperidone | 25 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 24 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 21 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 16 |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 15 |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Clonidine | Clonidine | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Ofloxacin | Ofloxacin | 16 | 13 |
| Olanzapine | Olanzapine | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Movantik | Naloxegol Oxalate | 14 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Repaglinide | Repaglinide | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Diclofenac Sodium-Misoprostol | Diclofenac Sodium/Misoprostol | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Nexletol | Bempedoic Acid | 12 | suppressed |
| Pimecrolimus | Pimecrolimus | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Constulose | Lactulose | 11 | suppressed |
| Heather | Norethindrone | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $190.26 · 9 records | PFIZER INC. | ELIQUIS, ENTRESTO, JARDIANCE, LEQVIO, NURTEC ODT, OTEZLA, REPATHA, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error